Current treatment of advanced melanoma. Dermatooncology update 2022

The medical treatment options of advanced cutaneous and mucosal melanoma markedly improved during the last 10 years. This improvement is due to checkpointinhibitors targeting PD-1 and CTLA-4 as well as tyrosine kinase inhibitors targeting BRAF and MEK. Current studies investigate new checkpoints such as LAG-3 as well as combinations and sequences of immune and molecular targeted therapies. Also in metastatic uveal melanoma a new option arises with tebentafusp. The current standard of care and clinical study activities are summarized in this article.